Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals and keeping the price target at $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein’s rating is based on the promising early launch performance of Ekterly, KalVista Pharmaceuticals’ new oral therapy for hereditary angioedema. The initial launch metrics show strong physician adoption and patient reach, with 460 patient start forms received, representing about 5% of the US HAE patient population. This early adoption is supported by the activation of 253 unique prescribers, 38% of whom have initiated treatment for multiple patients.
Fein also highlights the strategic commercial infrastructure that KalVista has invested in, which has facilitated broad physician engagement, reaching 72% of the total physician base. The QuickStart program, which provides immediate access to Ekterly, is expected to drive sustained revenue growth as payer adoption and formulary access expand. These factors collectively suggest that Ekterly has the potential to become a foundational on-demand therapy, supporting Fein’s Buy rating for KalVista Pharmaceuticals.
Fein covers the Healthcare sector, focusing on stocks such as Biogen, Wave Life Sciences, and United Therapeutics. According to TipRanks, Fein has an average return of 16.1% and a 51.52% success rate on recommended stocks.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $28.00 price target.